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Abstract
Purpose and methods We reviewed the existing literature
on medical termination of pregnancy in cases of congenital
uterine malformation. Is medical termination of pregnancy
safe in the presence of a uterine anomaly? Can termination of
pregnancystillbeperformedwheninformationconcerningthe
presence of congenital uterine malformation is not available?
Results The risk of adverse outcome, i.e. uterine rupture,
was high in class 2 uterine anomalies, whereas the risks in
classes 3–6 were negligible. However, the very low inci-
dence of class 2 anomalies in pregnant women results in a
calculated risk of uterine rupture in medical termination of
pregnancy on the basis of this anomaly of 1 in 300,000
pregnancies. Ultrasound scanning is of limited diagnostic
value to diagnose congenital uterine malformations.
Conclusions The implications of uterine anomalies are
not an argument in the discussion whether to use miso-
prostol for termination of pregnancy in developing coun-
tries with scarce diagnostics tools.
Keywords Misoprostol  Uterine anomalies 
Diagnostic ultrasound scanning safety
Introduction
Of the 210 million pregnancies worldwide each year, 87%
occurs in developing countries. Twenty-two million
terminations of pregnancy per year of a total of 42 million
are legal within a local judicial system [1].
Medical abortion using prostaglandins became an
alternative method for surgical abortion of ﬁrst and second
trimester pregnancies in the early 1970s [2]. This procedure
appears to be an effective and safe method for abortion,
although it might bear certain risks for women with a
uterine anomaly.
The prevalence of congenital anomalies due to Mu ¨lle-
rian duct malfusion has been estimated between 0.1% in an
unselected population and 6% in women undergoing
diagnostic imaging [3, 4].
In the Netherlands, these congenital anomalies are
mostly detected before the termination of a pregnancy, as
ultrasound investigation is routine in early pregnancy.
However, detection is less likely in developing countries
since diagnostic tools are scarce [5].
There islittle knowledge about the risk ofserious adverse
outcome, i.e. uterine rupture in medical termination of
pregnancy in the presence of a uterine anomaly [6, 7].
In this paper we present a case report and a review of the
literature on the use of misoprostol for termination of
pregnancy in women with uterine anomaly. Published risk
percentages of uterine rupture in using misoprostol for
medical abortion enabled us to calculate this risk in a
population of pregnant women in developing countries
requesting abortion.
Background
Uterine anomaly
A review on uterine anomalies by Nahum et al. [6] showed
that congenital uterine anomalies affect 0.5% of women in
N. M. van der Veen  J. F. G. M. Brouns (&)  J. P. Doornbos
Department of Obstetrics and Gynecology, Zaans Medical
Centre, Julianaplein 58, 1502 DV Zaandam, The Netherlands
e-mail: brouns.j@zaansmc.nl
W. J. van Wijngaarden
Department of Obstetrics and Gynecology, Bronovo Hospital,
Bronovolaan 5, 2597 AX The Hague, The Netherlands
123
Arch Gynecol Obstet (2011) 283:1–5
DOI 10.1007/s00404-010-1561-7the general population and 0.2% in fertile women (47
studies were included in the review). The most common
anomalies are the symmetric or duplication anomalies,
including bicornuate uteri. Unicornuate uteri, resulting
from unilateral failure of normal Mu ¨llerian system devel-
opment, comprise 5% of all uterine anomalies. The vast
majority of these have a contralateral rudimentary uterine
horn of the non-communicating type, meaning that the
endometrial cavity does not communicate with cervix,
vagina, or contralateral hemi-uterus. This is often diag-
nosed at exploratory laparotomy after pregnancy related
uterine rupture [6, 7].
In these rudimentary horns (85% are non-communicat-
ing), approximately 1 in 76,000 pregnancies occur [8, 9].
Fertilization in these cases takes place through transperi-
toneal migration of sperm from the patent contralateral
fallopian tube [10].
Prostaglandins
In the 1990s, it became clear that misoprostol is an effec-
tive and cheap alternative to the traditionally used prosta-
glandins in obstetric practice. The way of action is similar
to other prostaglandins although various natural and syn-
thetic prostaglandins employ their action using different
receptors and different biochemical pathways. The natural
prostaglandins are rapidly metabolized in lung tissue.
Synthetic prostaglandins, such as misoprostol, bypass the
lung, thus prolonging their half-life.
Misoprostol has a strong uterotonic effect and is widely
used in obstetrical and gynecological practice.
In comparison to the traditional prostaglandins such as
dinoprostone and gemeprost used in obstetrics, miso-
prostol is cheap (one 0.2 mg tablet costs US$ 0.10–0.30),
easy to administer, and stable in light and hot climate
conditions.
It can be kept on the shelf for long periods of time
without losing any of its properties.
Misoprostol can be used safely for termination of
pregnancy in ﬁrst as well as in second trimester, in case of
a viable and nonviable pregnancy [2, 11–13]. It is a safe
and cost effective alternative to surgical abortion, in
resource poor countries [14].
Risk assessment
Women with major uterine anomalies have an increased
risk for uterine rupture during pregnancy and delivery [15].
This may be due to a developmental inferior musculature
of the uterine wall. Myometrial thickness decreases with
gestational age and, in addition, the uterine wall becomes
thinner as a result of uterine contractions [8, 9, 15].
These anatomical phenomena will probably be less
important in cases of symmetric anomalies such as didel-
phic, bicornuate, and septate uteri. However, for pregnan-
cies in (non-)communicating rudimentary uterine horns,
vaginal delivery is impossible and potentially dangerous
[15]. Induction of myometrial contractions is potentially
hazardous in such cases as uterine rupture may ensue.
If we consider all different subtypes according to the
classiﬁcation of congenital uterine anomalies of the
American Fertility Society ‘‘AFS’’ (1988, Fig. 1)i ti s
especially class II that poses an increased risk. Patients
with a class I anomaly have no reproductive potential, class
III and IV hardly have obstetrical complications and class
VI is considered a normal variant. Although the septate
uterus (Class V) is correlated with reproductive compli-
cations, there is no risk of uterine rupture since the mus-
culature is normally developed.
The prognosis of pregnancies in a rudimentary uterine
horn is poor with regard to both maternal and fetal outcome
(neonatal survival rate of 6% and maternal mortality rate of
Fig. 1 Classiﬁcation of
congenital uterine anomalies
according to the American
Fertility Society ‘‘AFS’’ (1988)
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1235.7 and 1.9% for non-communicating and communicating
horns, respectively) [9]. Rupture of the rudimentary horn
accounts for 82% of these maternal mortalities.
Nahum et al. mentioned 47% of reported pregnancies in
non-communicating horns to be ruptured, as did 52% of the
communicating horns resulting in an overall risk of about
50%. Of these ruptures, 67% occurred during the second
trimester and 13% in the ﬁrst trimester [9]. Induction of
uterine contractions with misoprostol is likely to cause
uterine rupture, especially in the second trimester. The
prevalence of uterine anomalies is 1 in 200 in the general
female population and 1 in 590 in the fertile female pop-
ulation [6]. As the estimated risk of the class II uterine
anomaly is 5% (Figs. 2, 3), the prevalence of class II
anomaly is 1/11880 fertile women (Figs. 2, 3). Pregnancy
in a rudimentary horn occurs in 1/76,000 [16]. Little is
known about racial differences in the prevalence of con-
genital uterine malformations.
With a sensitivity of ultrasound scanning to detect a case
of rudimentary horn of 26% [7], 292,307 scans have to be
made to prevent one possible case of uterine rupture
(assuming the risk of rupture is 100% in case of a rudi-
mentary horn).
Case
A 32-year-old primigravida presented herself at our out-
patient department requesting a termination of pregnancy.
Ultrasound scan revealed a vital intrauterine pregnancy of
8 weeks and a uterine anomaly in the form of a class II or a
class III malformation (unicornuate uterus with a rudi-
mentary horn or a uterus didelphys). Generally in our clinic
all women requesting a termination of pregnancy are
counseled for a surgical as well as a medical procedure
General  
Population 
Uterus  
Anomaly 
0,5 % 
Normal 
Uterus 
99.5% 
Bicornuate Uterus 
39% 
Other forms 
4% 
Unicornuate uterus 
5% 
Arcuate uterus 
7% 
Didelphic uterus 
11% 
Septate uterus 
34% 
With rudimentary 
horn 
74% 
Without rudimentary 
horn 
26% 
Cavity 
50% 
Without cavity 
50% 
Non- 
communicating 
cavity 
72-92%
Communicating 
cavity 
8-28% 
Fig. 2 Distribution of uterine anomalies [8]
Uterus anomaly 0,2% 
= 1:594 
Class II 5% 
= 1:11880 
Rudimentary horn 74% 
= 1:16054 
No rudimentary horn 
26% 
With cavity 50% 
= 1:32108 
No cavity 50% 
Fig. 3 Prevalence of uterine anomalies in fertile women
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Although our patient preferred a medical procedure, the
attending physician doubted the safety of medical termi-
nation with misoprostol, deciding upon the surgical pro-
cedure instead.
Literature search
A systematic search was performed in PubMed and
Cochrane, using the search terms: ‘‘uterine anomaly,’’
‘‘uterine abnormalities,’’ ‘‘misoprostol,’’ ‘‘Mu ¨llerian
anomaly,’’ ‘‘rudimentary uterine horn,’’ ‘‘unicornuate
uterus,’’ and ‘‘bicornuate uterus’’.
Only three case reports and one accompanying report
have been published which matched our search.
In two of these case reports, termination of pregnancy
with misoprostol resulted in uterine rupture of the non-
communicating rudimentary horn [17, 18]. Chao et al. [19]
report the case of an incomplete medical abortion in a twin
pregnancy in a bicornuate uterus. Nahum et al. [15] suggest
a development of a set of practical guidelines.
Discussion
Since the introduction of misoprostol, there has been
concern about its safety. The manufacturer has sent several
warning letters against the unlicensed use of misoprostol
during pregnancy [20].
Risks concerning the use of misoprostol are its terato-
genic properties, hyperstimulation of the uterus, pregnancy
loss and uterine rupture. Most of these safety issues have
been addressed. Regimens used in obstetric and gyneco-
logical practice that are in accordance with professional
guidelines are considered effective and safe [13, 21].
These guidelines, based on best available evidence,
presume that the medical workup before a termination of
pregnancy is carried out, is up to standard. Physical
examination and access to ultrasound diagnostics are
essential in this. Ultrasound scanning can give an accurate
estimation of gestational age, reducing the incidence and
severity of complications [22], but can also reveal the
presence of uterine anomalies. Unfortunately, sensitivity of
ultrasound scanning is only 26% in cases of corneal
pregnancy [7]. Generally the identiﬁcation of uterine
anomalies is difﬁcult and will need well-trained personnel.
Criteria for recognition have been listed by Mavrelos et al.
[23]. During an established pregnancy, ascertaining the
exact type of mullerian anomaly is extremely challenging,
with a deﬁnite diagnosis of the subclass being possible only
outside pregnancy.
Most pregnant women in developing countries do not
have access to ultrasound investigations or even physical
examinationbyskilledprofessionals[1,24].Evenso,aclass
II anomaly can be easily missed on routine examination in
the absence of an associated cervical or vaginal abnormality
[6]. Particularly for this group of women, it is important to
know whether the administration of misoprostol is safe
withoutanyknowledgeonthepresenceofauterineanomaly.
Conclusion
The precise risks of uterine rupture with misoprostol for
termination of pregnancy in the presence of uterine
anomalies are not known. Only a few case reports are
available. There is still a lack of evidence of safety for the
use of misoprostol in settings where diagnostic and thera-
peutic tools are scarce. The relatively low frequency of
these uterine anomalies indicates that on a large scale, the
drug is safe, but the exact rate of complications in women
affected by Mullerian anomalies remains unknown and is
possibly higher than in the general population. Calculations
on the prevalence of uterine malformations and the inci-
dence of possibly related serious complications in cases of
termination of pregnancy support our opinion that diag-
nostic ultrasound scanning prior to medical termination of
pregnancy to rule out a potentially dangerous uterine
anomaly is not mandatory, although large scale studies
would be needed to provide a deﬁnitive answer toward the
need of ultrasound scanning.
Caring for pregnant women with congenital uterine
malformations can be particularly challenging, with
increased risks of complications arising from surgical and
medical ToPs alike. These women might beneﬁt from
individualized protocols (e.g. lower doses, use of mifepri-
stone prior to misoprostol).
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